The American Board of Bioanalysis (ABB) submitted comments today, February 14, 2019, in response to New York's proposed rule making to recognize ABB as a certifying board for high complexity clinical laboratory directors. View ABB's comments.
We urge you to submit comments supporting this proposal. Public comments are due by close of business on Monday, February 18, 2019. Comments should be forwarded (we recommend by email) to:
DOH Bureau of Program Counsel
Reg. Affairs Unit
ESP Tower Building
Albany, NY 12237
If you submit comments, please forward a copy to the ABB office.